NRF2 modulators/inhibitors (e.g. luteolin, ascorbic acid, tretinoin) might prove helpful in treating KRAS/KEAP-mutant cancers [69] (Fig. 1); 2 clinical trials are currently underway investigating the clinical efficacy of ascorbic acid (NCT03146962) and tretinoin (NCT04919369) in NSCLC and RAS-driven cancers respectively (Table 1). Here, KRAS is linked to non-small cell lung carcinoma.